Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG. Basser RL, et al. Among authors: fox rm. Blood. 1997 May 1;89(9):3118-28. Blood. 1997. PMID: 9129014 Free article. Clinical Trial.
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.
O'Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O'Byrne J, Green MD, Fox RM, Berndt MC, Begley CG. O'Malley CJ, et al. Among authors: fox rm. Blood. 1996 Nov 1;88(9):3288-98. Blood. 1996. PMID: 8896392 Free article. Clinical Trial.
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
Basser RL, To LB, Begley CG, Maher D, Juttner C, Cebon J, Mansfield R, Olver I, Duggan G, Szer J, Collins J, Schwartz B, Marty J, Menchaca D, Sheridan WP, Fox RM, Green MD. Basser RL, et al. Among authors: fox rm. J Clin Oncol. 1998 May;16(5):1899-908. doi: 10.1200/JCO.1998.16.5.1899. J Clin Oncol. 1998. PMID: 9586908 Clinical Trial.
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
Basser RL, To LB, Collins JP, Begley CG, Keefe D, Cebon J, Bashford J, Durrant S, Szer J, Kotasek D, Juttner CA, Russell I, Maher DW, Olver I, Sheridan WP, Fox RM, Green MD. Basser RL, et al. Among authors: fox rm. J Clin Oncol. 1999 Jan;17(1):82-92. doi: 10.1200/JCO.1999.17.1.82. J Clin Oncol. 1999. PMID: 10458221 Clinical Trial.
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
Talbot SM, Westerman DA, Grigg AP, Toner GC, Wolf M, Bishop J, McKendrick J, Zalcberg J, Levi J, Fox RM, Green MD. Talbot SM, et al. Among authors: fox rm. Ann Oncol. 1999 Aug;10(8):907-14. doi: 10.1023/a:1008353522601. Ann Oncol. 1999. PMID: 10509151 Free article. Clinical Trial.
220 results